Integra LifeSciences Holdings Full Year 2023 Earnings: EPS Misses Expectations
Integra LifeSciences Holdings (NASDAQ:IART) Full Year 2023 Results
Key Financial Results
Revenue: US$1.54b (down 1.0% from FY 2022).
Net income: US$67.7m (down 63% from FY 2022).
Profit margin: 4.4% (down from 12% in FY 2022).
EPS: US$0.84 (down from US$2.18 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Integra LifeSciences Holdings EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 30%.
Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 18% from a week ago.
Risk Analysis
Be aware that Integra LifeSciences Holdings is showing 3 warning signs in our investment analysis and 1 of those is a bit concerning...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
